Skip to content
Research Article Open access CC BY 4.0

IL-6 Blockade Limitations as an Anticancer Strategy: Literature Review and Proposal of Explanations for Unexpected Results

Mohamed Islam Delma

Asian Oncology Research Journal · pp. 1–5 · Published 10 Jan 2020

Abstract

IL-6 is a cytokine with multiple protumorigenic effects, making it an interesting therapeutic target. IL-6 inhibitors with an acceptable safety profile had been developed and tested in experimental and clinical trials. However, the outcomes were not as expected theoretically. Possible explanations of this discordance had been advocated by authors and will be reviewed in this paper. Additional reasons, such as the antitumoral effects of IL-6 and overcompensation by alternative agents will be proposed. These may also explain the trending to negative results constated in some clinical trials. 

Il-6 cxcl-12 pre-metastatic niche siltuximab

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.